Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
Original Article
M.D. Galsky, B.P. Valderrama, M. Maruzzo, A. Font, T. Ciuleanu, J. Chatzkel, T. Koie, C.J. Hoimes, J. Puente, Y. Zakharia, E. Rosenbaum, K. Boehm, Y. Loriot, J. Bedke, T.B. Powles, A. Necchi, P. Wiechno, C. Álvarez-Fernández, T.-H. Kim, N. Oliveira, T.W. Flaig, H.S. Wirtz, M. Mihm, Q. Huang, A. Rogiers, B.H. Moreno, and A.G.d. Liaño
N Engl J Med 2026;395:338-348
Course summary
Available credit:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Course opens:
07/22/2026
Course expires:
07/23/2028
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Please sign in or create an account to take the course.

Facebook
X
LinkedIn
Forward